<p>Pancreatic cancer is a malignant solid tumour that contains a large number of cancer-associated fibroblasts (CAFs). Therefore, evaluating tumour disease progression and planning radionuclide therapy using molecular imaging of CAF biomarkers are crucial. Platelet-derived growth factor receptor β (PDGFRβ) is highly expressed in fibroblasts, and a specific affinity probe, Z_PDGFRβ, that binds to PDGFRβ was successfully developed. In this study, ⁴⁷Sc was used to label the affibody targeting PDGFRβ to explore its distribution characteristics in pancreatic cancer and the therapeutic effect of radionuclides. ⁴⁷Sc was produced using thermal neutron irradiation-enriched ⁴⁶Ca with a radionuclide purity greater than 99.9%. The Z_PDGFRβ affibody was radiolabelled with ⁴⁷Sc to obtain a ⁴⁷Sc-DOTA-Z_PDGFRβ conjugate with a radiochemical purity greater than 99%. Biodistribution studies revealed that tumour uptake of ⁴⁷Sc-DOTA-Z_PDGFRβ reached 4.57 ± 2.12% ID/g at 1&#xa0;h postinjection and 4.00 ± 0.71% ID/g at 96&#xa0;h postinjection. However, the uptake by the liver and kidneys reached 10.44 ± 3.19% ID/g and 49.90 ± 8.89% ID/g, respectively, at 1&#xa0;h postinjection. Then, the uptake was reduced to 2.20 ± 1.04% ID/g and 2.60 ± 0.27% ID/g at 96&#xa0;h postinjection. Single-photon emission computed tomography (SPECT) imaging indicated specific uptake of ⁴⁷Sc-DOTA-Z_PDGFRβ in PANC-2 pancreatic tumours. Similar to 177Lu, ⁴⁷Sc exhibits an effective antitumour ability. Our results indicated that the ⁴⁷Sc-DOTA-Z_PDGFRβ conjugate exhibited remarkable targeting efficacy as a PDGFRβ-targeted radiotracer in SPECT imaging and demonstrated favourable radiotherapy capabilities. SPECT imaging of ⁴⁷Sc ions also revealed characteristic distribution patterns in the cardiac, aortic, and hepatic regions, which has significant implications for future pharmaceutical development and radiation side effect prediction.</p>